Cardiovascular disease primary

Hypertension is one of the two principal risk factors of many cardiovascular diseases, such as coronary heart disease (CHD), stroke, and CHF. Individuals are considered hypertensive if their systoHc arterial blood pressure is over 140 mm Hg (18.7 Pa) or their diastoHc arterial blood pressure is over 90 mm Hg (12 Pa). Over 60 million people, or one-third of the adult population in the United States are estimated to be hypertensive (163). About 90% of these patients are classified as primary or essential hypertensive because the etiology of their hypertension is unknown. It is generally agreed that there is a very strong genetic or hereditary component to this disease. 

The nurse carefully observes patients with cardiovascular disease taking the thyroid hormones. The development of chest pain or worsening of cardiovascular disease should be reported to the primary health care provider immediately because the patient may require a reduction in the dosage of the thyroid hormone. 

Everybody suffers some intellectual and memory impairment with age. If it becomes very marked or occurs earlier in life (40+) it is known as dementia. Although it may be caused by alcoholism, cardiovascular disease such as multiple infarcts, and is often seen in the later stages of Parkinsonism, the most common cause is a neurodegenerative one, namely, Alzheimer s disease (AzD). In fact this is the primary and sole cause in over half the cases of dementia and is a contributory cause in a further quarter and the younger the patient, the more likely is the dementia to be of the Alzheimer type. 

Observational studies have suggested possible favourable effects of estrogen replacement therapy (ERT) on the risk of coronary heart disease in postmenopausal women. Since elevated plasma cholesterol has been identified as the primary risk factor for cardiovascular disease, investigations have focused on the inverse association between plasma cholesterol concentration and soy protein consumption. The cholesterol-lowering properties of soy have been demonstrated, and a good correlation has been found in... 

Many epidemiological studies have analyzed the correlations between different carotenoids and the various forms of cancer and a lot of conclusions converge toward protective effects of carotenoids. Many studies were carried out with (i-carotene. The SUVIMAX study, a primary intervention trial of the health effects of antioxidant vitamins and minerals, revealed that a supplementation of p-carotene (6 mg/day) was inversely correlated with total cancer risk. Intervention studies investigating the association between carotenoids and different types of cancers and cardiovascular diseases are reported in Table 3.1.2 and Table 3.1.3. 

Symptoms The primary hypertension patient may be asymptomatic or may have major cardiovascular disease risk factors. 

Hyperlipidemia plays a role in the development of cardiovascular disease (CVD) in patients with CKD. The primary goal of treatment of dyslipidemras is to decrease the risk of atherosclerotic cardiovascular disease. A secondary goal in patients with CKD is to reduce proteinuria and decline in kidney function. Treatment of hyperlipidemia in patients with CKD has been demonstrated to slow the decline in GFRby 1.9 mL/minute per year of treatment with antihyper Epidemic agents.21... 

Hyperlipidemia is seen in up to 60% of heart, lung, and renal transplant patients and greater than 30% of liver transplant patients.64 66 As a result of elevated cholesterol levels, transplant recipients are not only at an increased risk of atherosclerotic events, but emerging evidence also shows an association between hyperlipidemia and allograft vasculopathy.66 Hyperlipidemia, along with other types of cardiovascular disease, is now one of the primary causes of morbidity and mortality in long-term transplant survivors.67... 

In addition to effects on bone, raloxifene may have effects in breast tissue and on the cardiovascular system. A secondary end point of the MORE trial evaluated the effects of raloxifene on the primary prevention of breast cancer and found a significant reduction in all types of breast cancer.33 Raloxifene decreases total and low-density lipoprotein (LDL) cholesterol,34 and studies are evaluating its effect on reducing the risk of cardiovascular disease.35... 

The primary goal of lipid-lowering therapies in CKD is to decrease the risk for progressive atherosclerotic cardiovascular disease (Table 76-1). 

Hormone therapy has proven highly effective in controlling the menopausal syndrome, especially severe hot flushes (MacLennan et al. 2004), even at doses significantly lower than those used until now (Speroff et al. 2000 Utian et al. 2001). Women s Health Initiative studies found that hormone replacement therapy, when administered as a primary prevention intervention for CVD in older women, increases the risk of heart disease and breast cancer. Even if a protective effect on fracture and colon cancer was observed, the risk-benefit ratio led to a recommendation of this treatment only for the short-term relief of menopausal symptoms (Rossouw et al. 2002 Anderson et al. 2004). The role of early administration of ovarian hormones to young postmenopausal women in the prevention of cardiovascular disease or late dementia remains... 

The role of Lp(a) as a primary genetic risk factor for coronary heart disease, therefore, seems firmly established. However, in blacks, despite mean Lp(a) levels twice as high as in whites, the incidence of cardiovascular disease is apparently identical (G37, S40). The role of Lp(a) in atherosclerotic vascular disease in blacks therefore remains to be established. 

LDL (low-density lipoprotein) the primary carrier of cholesterol in the blood a positive risk factor for cardiovascular disease bad cholesterol. ... 

The results of several large clinical trials using the statin drugs (discussed later) show that the tested drugs decreased the risk of both primary and secondary cardiovascular events. The incidence of myocardial infarction and death from cardiovascular disease was reduced in patients with hypercholesterolemia who never had a... 

The doxazosin arm of the ALLHAT study was stopped early the doxazosin group had a 25%greater risk of combined cardiovascular disease events which was primarily accounted for by a doubled risk of CHF vs the chlorthalidone group doxazosin was also found to be less effective at controlling systolic BP an average of 3 mm Hg may want to consider primary antihypertensives in addition to a-blockers for BPH symptoms... 

Standard lipid screening to obtain a cholesterol profile for the risk of cardiovascular disease routinely reports total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides. Cholesterol values are reported in milligrams per deciliter of blood (mg/dL). Different organizations have made recommendations for normal cholesterol levels, but these must be interpreted carefully, as they are contingent on other risk conditions. For example, the recommendations for smokers or those with a family history of heart disease will be lower for someone without these conditions. The National Center for Cholesterol Education (NCEP) endorsed by the American Heart Association believes that LDL is the primary cholesterol component to determine therapy. LDL cholesterol accounts for 60—70% of blood serum cholesterol. An LDL less than 160 mg/dL is recommended for individuals with no more than one risk factor and less than 100 mg/dL for individuals with coronary heart disease. NCEP classifies HDL, which comprises between 20% and 30% of blood cholesterol, below 40 mg/dL as low. Triglycerides are an indirect measure of VLDL cholesterol. The NCEP considers a normal triglyceride level as less than 150 mg/dL. 

Hyperlipidemia, an abnormally high concentration of lipids in the bloodstream, is one of the primary causes of cardiovascular disease in industrialized nations. This condition typically causes deposition of fatty plaquelike lesions on the walls of large and mediumsized arteries atherosclerosis), which can lead to throm-... 

Cardiovascular disease is a primary risk factor during estrogen and progesterone therapy. Higher doses or prolonged exposure to estrogen has been associated... 

In view of the perceived benefit of aspirin in the secondary prevention of stroke and myocardial infarction, two large trials involving physicians as subjects were initiated to study the effect of aspirin in the primary prevention of arterial thrombosis. In the American study, 22,000 volunteers (age 40 to 84 years) were randomly assigned to take 325 mg of aspirin every other day or placebo. The trial was halted early, after a mean follow-up of 5 years, when a 45% reduction in the incidence of myocardial infarction and a 72% reduction in the incidence of fatal myocardial infarction were noted with aspirin treatment. However, total mortality was reduced only 4% in the aspirin group, a difference that was not statistically significant, and there was a trend for a greater risk of hemorrhagic stroke with aspirin. Thus, the prophylactic use of aspirin in an apparently healthy population is not recommended at this time, unless there are risk factors for cardiovascular disease. 

Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS) multicentre randomised placebo-controlled trial. Lancet 2004 364 685-696. 

---